Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Burzynski Research Institute
ClinicalTrials.gov Identifier:
NCT00003473
First received: November 1, 1999
Last updated: September 12, 2016
Last verified: September 2016
Results First Received: August 24, 2016  
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Mixed Gliomas
Intervention: Drug: Antineoplaston therapy (Atengenal + Astugenal)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Twenty patients were recruited between March 1996 and May 2008. All study subjects were seen at the Burzynski Clinic in Houston TX

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Antineoplaston Therapy

Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Antineoplaston therapy (Atengenal + Astugenal): Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).


Participant Flow:   Overall Study
    Antineoplaston Therapy
STARTED   20 
COMPLETED   17 [1] 
NOT COMPLETED   3 
[1] Three patients were not evaluable.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Antineoplaston Therapy

Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Antineoplaston therapy (Atengenal + Astugenal): Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).


Baseline Measures
   Antineoplaston Therapy 
Overall Participants Analyzed 
[Units: Participants]
 20 
Age 
[Units: Years]
Median (Full Range)
 37.3 
 (26.7 to 54.3) 
Gender 
[Units: Participants]
 
Female   6 
Male   14 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Objective Response   [ Time Frame: 12 months ]

2.  Secondary:   Percentage of Participants Who Survived   [ Time Frame: 6 months, 12 months, 24 months, 36 months, 48 months, 60 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: S. R. Burzynski, MD, PhD
Organization: Burzynski Research Institute, Inc.
phone: 713-335-5664
e-mail: srb@burzynskiclinic.com



Responsible Party: Burzynski Research Institute
ClinicalTrials.gov Identifier: NCT00003473     History of Changes
Other Study ID Numbers: CDR0000066510
BC-BT-18 ( Other Identifier: Burzynski Research Institute, Inc. )
Study First Received: November 1, 1999
Results First Received: August 24, 2016
Last Updated: September 12, 2016
Health Authority: United States: Food and Drug Administration